Topical Cetirizine for Hair Loss: Can an Antihistamine Regrow Hair?
Published by AmpleLab Research
Cetirizine is a second-generation antihistamine, sold over the counter for hay fever and hives. It has no obvious connection to hair. The rationale for using it on the scalp comes from a specific molecular pathway involved in pattern hair loss, one that cetirizine happens to interact with through a mechanism separate from the one it's actually approved for. Since 2018, that rationale has been tested in a handful of small clinical trials, comparing topical cetirizine against placebo, against minoxidil directly, and as an add-on to minoxidil.
This article covers the mechanism behind the idea, what the trials have found so far, and where cetirizine lands against minoxidil when tested head-to-head, which turns out to be a less flattering comparison than most cetirizine-focused content lets on.
Why an Antihistamine, Specifically
The starting point is a 2012 discovery about prostaglandin D2, a signalling lipid that turned out to actively suppress hair growth rather than being a passive bystander in balding.
Researchers compared bald and haired scalp from the same men with androgenetic alopecia and found the enzyme prostaglandin D2 synthase (PTGDS), and its product prostaglandin D2 (PGD2), elevated at the mRNA and protein level specifically in bald scalp. In mice, PGD2 levels rose immediately before the hair follicle's regression phase during normal cycling. Applied directly to explanted human hair follicles and to mouse skin, PGD2 and a related metabolite inhibited hair growth, acting through a receptor called GPR44 rather than the more commonly discussed PGD2 receptor, PTGDR. This established PGD2 as an active inhibitory signal in balding scalp, not simply a marker of it, and made lowering PGD2 a plausible therapeutic target.
Cetirizine's link to PGD2 predates the Garza study by more than two decades, and comes from allergy research rather than hair research. This is worth being precise about, since it's the connection every subsequent hair trial relies on without re-establishing it in scalp tissue.
Ten ragweed-allergic subjects took oral cetirizine or placebo before an induced allergic skin reaction. Histamine release was unaffected by cetirizine, but PGD2 production fell at every measured time point, with roughly 50% suppression at the reaction's fifth hour. Inflammatory cell infiltration, eosinophils and neutrophils in particular, dropped by around 75% during the later hours of the reaction. The authors concluded the effect worked through reduced inflammatory cell recruitment rather than through cetirizine's labelled H1-antihistamine action. This is a study of oral cetirizine in an allergic skin reaction, not topical cetirizine in a hair follicle, and it's the mechanistic starting point cited by the subsequent AGA literature.
The Study That Started the Cetirizine-for-AGA Idea
An Italian group led by Alfredo Rossi ran the first trial actually testing topical cetirizine against placebo in AGA patients, publishing in 2018.
Eighty-five patients with AGA were recruited, 67 treated with daily 1% topical cetirizine and 18 serving as controls. The treated group showed a statistically significant increase in total hair density, terminal hair density, and hair shaft diameter, alongside a decrease in vellus (fine, unpigmented) hair density, a shift generally read as a move toward thicker, more mature hair. No notable side effects were reported. As a first pilot study, this established a testable signal rather than a confirmed effect: it set up the later trials rather than settling the question on its own.
A Larger Case-Controlled Trial in Men
A 2021 Egyptian study followed 60 men over six months, a considerably longer treatment window than the 2018 pilot.
Sixty men with AGA were split into two groups of 30, one applying daily 1% topical cetirizine, the other a placebo solution, for six months. Dermatological and dermoscopic assessment found hair regrowth in 43.3% of the cetirizine group versus 0% of the placebo group, a significant difference. Blinded photographic assessment of Hamilton-Norwood grade showed the same 43.3% improvement rate in the cetirizine group against 0% in the placebo group. Patient self-assessment tracked closely with both objective measures, at 43.3% reporting improvement versus 0%. This was a placebo-controlled rather than an untreated-control design, which provides a stronger comparison than simply observing an untreated group, although the study was still relatively small and the authors themselves called for further randomised, controlled trials.
Where It Lands Against Minoxidil, Directly
The most informative trials for anyone deciding between the two are the ones that tested cetirizine directly against minoxidil, rather than against placebo alone. The first was run in men.
Forty men aged 18 to 49 were randomised into two equal groups, applying either 1% cetirizine or 5% minoxidil twice daily for 16 weeks, followed by an 8-week placebo washout period. Using TrichoScan for objective measurement, both groups showed significant increases in total hair density and vellus hair density, and the percentage of hair in anagen (active growth) phase rose in both groups before declining during the washout. The improvement was substantially larger in the minoxidil group. On physician-rated assessment, 17% of the cetirizine group showed a reduction in hair density rather than improvement, versus 0% in the minoxidil group. Patients in the minoxidil group reported greater treatment satisfaction. Cetirizine improved hair density, but the improvement was substantially smaller than with minoxidil, the clearest evidence in this literature that it does not match minoxidil's effect at standard concentrations.
Another Head-to-Head Trial, in Women
A second direct comparison against minoxidil, this time in female pattern hair loss, reached a similar conclusion to the Mostafa trial in men.
A triple-blind randomised trial assigned 60 women with female pattern hair loss to either 1% topical cetirizine or 2% topical minoxidil for six months, with hair diameter and density assessed by trichoscopy. Both groups improved on both measures, but the improvement reached statistical significance only in the minoxidil group. Per-protocol analysis found minoxidil significantly superior to cetirizine on hair density, though not on hair diameter, where the two treatments performed comparably. Hair loss severity scores improved significantly in both groups. Dropout due to adverse effects was low in both arms, 10.0% with cetirizine and 6.6% with minoxidil. The authors' own framing was that cetirizine, while inferior to minoxidil overall, may still suit patients who cannot tolerate minoxidil.
As an Add-On to Minoxidil, in Women
One of the strongest-controlled trials in this body of research tested cetirizine not as a replacement for minoxidil but as an addition to it, in female pattern hair loss.
Sixty-six women with female pattern hair loss, Sinclair grades II to IV, were randomised in a double-blind, placebo-controlled design to either cetirizine plus minoxidil or placebo plus minoxidil for 24 weeks. Both groups improved, which is expected given both received minoxidil. The cetirizine-plus-minoxidil group showed a significantly greater increase in vertex hair shaft thickness and a higher number of hairs per follicular unit than the minoxidil-only group, along with better patient self-assessment scores. Side effects did not differ significantly between groups. This is the best-controlled trial in the cetirizine literature, and its finding is narrower than "cetirizine works": it supports cetirizine as a possible add-on that improves specific measures alongside minoxidil, not as evidence it works as a standalone substitute.
Two Additions From 2025
Two more trials published in 2025 add to the picture, though neither changes the overall conclusion, and one complicates it in an interesting way.
Eighty men with AGA were randomised, single-blind, to eight weeks of 1% cetirizine delivered by microneedling or saline delivered by microneedling as a placebo-controlled comparison. The cetirizine group showed enhanced hair density in 80% of patients versus 25% with saline, a significant difference. At week eight, 70% of the cetirizine group also showed vellus hair present versus 30% of the saline group, also significant. This is a different delivery method from the earlier trials, with topical cetirizine administered using microneedling rather than conventional topical application, and it uses a different outcome measure for its vellus hair finding. Worth flagging a tension rather than smoothing over it: the 2018 Rossi trial found cetirizine associated with a decrease in vellus hair density, read as a shift toward thicker, more mature hair, while this trial found cetirizine associated with an increase in vellus hair presence. The two studies measured different things, prevalence of any vellus hair versus density as a proportion of total hair, so they aren't a direct contradiction, but they aren't simply consistent either, and the difference in delivery method makes a clean comparison difficult.
Ten men with AGA applied daily 1% cetirizine for 16 weeks in an open-label study with no placebo or comparator arm. Nine completed the study. Mean hair count in a tattoo-marked vertex area rose from 139.6 to 163.4, a statistically significant change (p=0.009), and trichoscopic counts improved in every completer, with no adverse events reported. Blinded global photographic assessment told a more modest story: one patient showed a two-point improvement, two showed a one-point improvement, and six showed no visible change on that scale. This is the weakest design tier of the trials covered here, open-label with no control group of any kind, and it illustrates something worth remembering across all of these studies: a statistically significant hair count increase and a visually apparent change on blinded assessment don't always move together, and photographic assessment is generally the harder bar to clear.
What This Adds Up To
The mechanistic case for cetirizine is more indirect than it first appears. PGD2's role in suppressing hair growth is well established in scalp tissue specifically, from the Garza 2012 work. Cetirizine's ability to lower PGD2, however, comes from a 1989 study of oral cetirizine in an unrelated allergic skin reaction, not from any hair follicle model. The clinical trials since 2018 have therefore been testing whether topical cetirizine produces the expected effects in balding scalp, even though none has directly established PGD2 reduction as the mechanism at work on the treated scalp itself. A 2022 systematic review of the earlier literature, covering the trials published up to that point, likewise judged the available studies to carry moderate-to-high risk of bias and called for better-designed randomised trials; it predates several of the trials discussed above, but its methodological caution still applies to the body of evidence as a whole.
On the clinical evidence, seven small trials published between 2018 and 2025 have reported positive findings with topical cetirizine or cetirizine-containing regimens, involving 10 to 85 participants each, although the two 2025 additions differ substantially in delivery method, study design, and outcome assessment, and are not directly comparable with the earlier trials. Against minoxidil directly, cetirizine underperformed on the most consistently measured outcome, hair density, across both trials that tested it head-to-head, including a meaningfully higher rate of patients in one trial whose hair density declined during treatment; differences on hair diameter were less consistent, with one trial finding no significant gap between the two. As an add-on to minoxidil rather than a substitute for it, one of the strongest-controlled trials in this body of research found a modest additional benefit on shaft thickness and follicular unit count. Side effect profiles across these trials were generally favourable, with cetirizine appearing well tolerated at the concentrations tested.
The evidentiary tier matters here as much as the direction of the results. These are small trials, several open-label or single-blind rather than fully blinded, from a handful of research groups, without independent replication at scale by researchers outside the original teams. That's enough to support cetirizine as a potentially useful, apparently well-tolerated addition worth discussing with a dermatologist, particularly alongside minoxidil rather than in place of it. It isn't enough to support cetirizine as an established, minoxidil-equivalent treatment on its own.
Frequently Asked Questions
Why would an antihistamine affect hair growth?
Not through its antihistamine action. A 2012 study found prostaglandin D2 elevated in bald scalp and directly suppressing hair growth in explanted follicles. Separately, a 1989 allergy study found oral cetirizine lowers PGD2 production through reduced inflammatory cell activity, a mechanism the study's own authors said was unrelated to cetirizine's H1-blocking effect. Hair trials since 2018 have tested whether that PGD2-lowering effect translates to topical use on the scalp.
Is topical cetirizine as effective as minoxidil?
No. Two trials have tested them head-to-head. In 40 men over 16 weeks, both improved hair density, but the improvement was substantially larger with minoxidil, and 17% of the cetirizine group's hair density declined during treatment versus 0% in the minoxidil group. In 60 women over six months, minoxidil was significantly superior on hair density, though the two performed comparably on hair diameter.
Can cetirizine be combined with minoxidil?
This is where the strongest evidence sits. A 66-woman, double-blind, placebo-controlled trial found cetirizine added to minoxidil produced greater hair shaft thickness and more hairs per follicular unit than minoxidil alone, with a comparable side effect profile.
Is topical cetirizine safe for the scalp?
Across the trials conducted so far, topical cetirizine at 1% has been well tolerated, with no significant excess of side effects reported compared to placebo or minoxidil. These trials remain small, and longer-term safety data at scale hasn't been established.
How strong is the evidence overall?
Seven clinical trials published from 2018 to 2025, all relatively small by clinical-trial standards, have reported positive findings with topical cetirizine, but they vary substantially in design, delivery method, and comparator. When the comparator is placebo, an untreated group, or saline, cetirizine has come out ahead in every trial that tested it that way. When the comparator is minoxidil itself, the two trials that made that comparison both found minoxidil producing greater improvements in hair density. This is a potentially useful option to discuss with a dermatologist rather than an established primary treatment.
Selected Research
This article is provided for educational purposes and does not constitute medical advice. Topical cetirizine for hair loss is not an FDA or MHRA-approved use of the medication; consult a dermatologist before starting it, particularly in combination with other treatments. AmpleLab products are cosmetic formulations, unrelated to cetirizine, and are not intended to diagnose, treat, cure, or prevent any condition.
AmpleLab.